AVAVA MIRIA General Use

Overview

A general protocol to treat a variety of dermatologic conditions and collect patient feedback. Primary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment. Secondary outcome measures include physician and subject evaluations in regards to improvement seen in the device as well as assessment of side effects.

Interventions

• Device AVAVA
  1550nm Non-Ablative Fractional Laser

Primary outcome measures

• Completion of Post-Treatment Subject Questionnaire [Time frame: Immediate Post-Treatment]

Secondary outcome measures (6)

• Blinded Assessment of Before and After Imaging by Trained Dermatologist [Time frame: Baseline, 3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment]
• Completion of Follow-Up Subject Questionnaire [Time frame: 3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment]
• Physician Rated Satisfaction [Time frame: Baseline, 3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment]
• Subject Rated Satisfaction [Time frame: Baseline, 3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment]
• Physician Rated Global Clinical Aesthetic Improvement Scale Scoring [Time frame: Baseline, 3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment]
• Subject tolerance of procedure based on pain score during treatment per Visual Analogue Scale [Time frame: Immediate Post Treatment]

Eligibility criteria

Inclusion criteria

• Male or female subjects between 18 to 70 years of age.
• Dermatologic condition that can be addressed by the laser, including but not limited to:

• Wrinkles
• Scars
• Acne Scars
• Active Acne
• Dyschromia
• Cutaneous Lesions such as Age or Sun Spots
• Melasma
• Laxity
• Willingness to have digital photographs taken of treatment area(s) and agreement with use of photographs for presentation, educational, or marketing purposes.
• Willingness to comply with the following during the study, including the follow-up period:

• maintain consistent skin care regimen on treated areas.
• cover treated areas or have very limited sun exposure and, if requested, use an approved sunscreen of SPF 50 or higher.
• refrain from using systemic corticosteroids, according to Investigator discretion.
• refrain from using topical corticosteroids, retinoids, or prescription skin-lightening medications on the treated areas, according to Investigator discretion.
• refrain from any other procedures in the treatment areas.
• Willingness and ability to comply with study instructions and return for required visits.
• Subject has read and signed a written informed consent form.
• Subject lives within 50 miles of study site.
• Willingness to shave hair in intended treatment area

Exclusion criteria

• Skin pathology or condition that could interfere with evaluation of the study procedure, e.g.,
• Systemic treatment prescribed within previous 6 months (e.g., oral medication such as isotretinoin)
• Surgical treatment in the target areas within previous 6 months (e.g., laser surgery)
• Active vitiligo, psoriasis, or eczema in the treatment area
• Injection of dermal filler in the target areas within previous 1 month (e.g., collagen, hyaluronic acid filler)
• Cosmetic procedures in the target areas within prior 3 months (e.g., laser, microdermabrasion, skin peel)
• Topical treatment applied to target areas within the previous 1 month or according to Investigator discretion.
• Active suntan and unable or unlikely to refrain from tanning within the follow-up period.
• Artificial tanning in the target areas within the previous 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period.
• Active localized or systemic infection, or an open wound in area being treated.
• Lesions in the treatment areas suspicious for malignancy (skin cancer, melanoma)
• History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid)
• History of connective tissue disease, such as lupus or scleroderma.
• Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals that produce sensitivity to light may be used in areas other than the target area).
• History of gold therapy.
• History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
• History of radiation to the treatment area or currently undergoing systemic chemotherapy for the treatment of cancer.
• For Female: Pregnancy or lactation, or intent to become pregnant within the study period.
• Significant uncontrolled concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
• History of immunosuppression/immune deficiency disorder or currently using immunosuppressive medications.
• Current enrollment in a clinical study of any other unapproved investigational drug or device
• Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• AVAVA, Inc. — Waltham

Identifiers

NCT: NCT06868615 · AV-24-003

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗